Aprea Therapeutics (NASDAQ:APRE) Shares Up 2.8% – Still a Buy?

Aprea Therapeutics, Inc. (NASDAQ:APRE) rose 2.8% during trading on Thursday . The stock traded as high as $0.8071 and last traded at $0.7830. Approximately 51,910 shares were traded during trading, a decline of 74% from the average daily volume of 196,794 shares. The stock had previously closed at $0.7620.

Analyst Ratings Changes

APRE has been the subject of several recent research reports. Oppenheimer initiated coverage on Aprea Therapeutics in a research report on Thursday, May 7th. They set an “outperform” rating and a $5.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research report on Monday, April 20th. Zacks Research raised Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. HC Wainwright reduced their price target on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, Wedbush reduced their price target on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Aprea Therapeutics has an average rating of “Hold” and an average target price of $4.07.

Aprea Therapeutics Price Performance

The company has a market capitalization of $9.69 million, a price-to-earnings ratio of -0.51 and a beta of 1.51. The stock has a 50-day moving average price of $0.85 and a 200-day moving average price of $0.87.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%.The company had revenue of $0.28 million during the quarter, compared to analysts’ expectations of $0.00 million. Equities analysts forecast that Aprea Therapeutics, Inc. will post -0.83 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A number of large investors have recently made changes to their positions in APRE. DRW Securities LLC bought a new position in shares of Aprea Therapeutics during the fourth quarter worth approximately $103,000. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics during the fourth quarter worth approximately $40,000. Finally, AIGH Capital Management LLC increased its stake in shares of Aprea Therapeutics by 174.1% during the first quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after purchasing an additional 645,000 shares during the period. Institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.